Best Healthcare Stocks this March 2026 in the UK

GSK (GlaxoSmithKline) stands out as a major player in the pharmaceuticals and vaccines sector, with a robust market cap of £56.44 billion and an impressive analyst upside potential of 46%. Investors can benefit from a solid dividend yield of 2.77% and notable returns of 43.43% over the past year and 73.94% over five years. However, recent analyst ratings have shifted, with SVB Leerink downgrading to Perform and Deutsche Bank issuing a Sell, indicating mixed sentiment in the market.

Smith & Nephew stands out as a leading medical devices manufacturer, having recently outperformed the FTSE 100 and received a price target increase from Barclays. With a current dividend yield of 2.14%, the company offers attractive potential for income-focused investors, despite experiencing a slight dip in 5-year returns. Analysts remain optimistic, with ratings including "Outperform" from Bernstein and a "Buy" from Canaccord Genuity, highlighting its growth prospects amidst recent revenue challenges.

SSNLF currently has 2 Buy Ratings and 1 Hold Rating, indicating a generally positive outlook.

Smith & Nephew PLC shares fell despite raising its annual free cash flow outlook, as third quarter revenue missed expectations.

Fusion Finance Ltd. has a price target of 197.50, suggesting an 8.42% upside from its current price of 182.17, but it has been downgraded by one broker.

Hikma Pharmaceuticals, recognized for its leadership in drug generics, is currently viewed as attractively undervalued with a price-to-earnings (P/E) ratio of just 9.3. This UK-listed company is not only improving accessibility to essential medications but also offers a robust dividend yield of 3.41%, making it an appealing option for income-focused investors despite a challenging year with a 39.66% decline in stock value. Analysts maintain a strong A- rating on Hikma, highlighting its potential for recovery and growth in the pharmaceutical sector.

Hikma appears undervalued with a price-to-earnings (P/E) ratio of 9.3 and a dividend yield of 4.1%, indicating both income and value potential.

Yes, Hikma pays dividends twice a year, typically in May and September, based on the company's annual profit.

Analysts have set a median target price of 2,360.43 for Hikma Pharmaceuticals, suggesting a potential 42.8% increase from its current price of 1,653.00.

Spire Healthcare, the UK's largest independent private hospital network, operates 72 facilities and focuses on a diverse range of medical services. Despite a challenging year resulting in a 15.11% decline in share price, the company has delivered a solid 24.62% return over the past five years, complemented by a dividend yield of 1.19%. Interestingly, investor sentiment remains optimistic, with all seven analysts providing buy ratings, indicating strong potential for recovery.

Investor sentiment is positive, with all seven analysts recommending buy ratings for Spire Healthcare.

The drop was attributed to a spending slowdown at integrated care boards, despite rising NHS budgets and ongoing waiting lists.

SPI stock carries risks such as wider spreads, increased volatility, and potential difficulties in selling due to unsolicited customer orders.